Metabolic epilepsies amenable to ketogenic therapies: Indications, contraindications, and underlying mechanisms.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and clinical indications without systematic search methods or original human data.
PubMed 32654164 · doi:10.1002/jimd.12283
What was done
This narrative review describes indications, contraindications, and proposed molecular mechanisms for ketogenic dietary therapies in metabolic epilepsies resulting from inborn errors of metabolism, such as glucose transporter type 1 deficiency, succinic semialdehyde dehydrogenase deficiency, pyruvate dehydrogenase complex deficiency, nonketotic hyperglycinemia, and mitochondrial cytopathies.
What was found
The abstract reports no numerical findings or comparative statistics. It summarizes mechanistic actions of ketogenic diets in these disorders, including restoration of bioenergetics, correction of synaptic dysfunction, improvement of redox homeostasis, anti-inflammatory activity, and epigenetic regulation, while highlighting absolute contraindications including fatty acid oxidation disorders.
Why it matters
It outlines the metabolic rationale for using ketogenic therapies in rare genetic epilepsies characterized by impaired energy production, helping clinicians navigate appropriate indications and dangerous contraindications.
Limits
This is a narrative review with no quantitative effect sizes, patient counts, or systematic methodology detailed in the abstract. Clinical efficacy, tolerability, and long-term outcomes are not quantified.
Cited by
- supports A ketogenic diet is medically contraindicated in patients with carnitine palmitoyltransferase deficiency (CPT-1 deficiency) and can be fatal.
- supports The ketogenic diet is a medically established and accepted treatment for glucose transporter type 1 deficiency syndrome and pyruvate dehydrogenase deficiency.